Three studies show that MiYOSMART works long-term, in combo with atropine and before myopia begins.
HOYA Vision Care (Tokyo, Japan) unveiled new data at the recently concluded ARVO 2025 Annual Meeting, strengthening the case for non-invasive Defocus Incorporated Multiple Segments (D.I.M.S.) Technology in managing—and potentially preventing—myopia in children.
The data—drawn from three key studies—spotlighted long-term wear benefits of MiYOSMART lenses, the added impact of pairing them with low-dose atropine and even the potential to prevent myopia before it starts.
These findings were part of HOYA’s scientific program, Exploring New Frontiers in Myopia Management with MiYOSMART, underscoring a multifaceted approach to tackling childhood myopia.
READ MORE: Specs and Control: Embracing the Promise of Myopia Control-Specific Spectacles
Eight years of follow-up: What long-term wear tells us
HOYA presented new results from the longest-running clinical study on myopia control using spectacle lenses. Researchers followed a group of children wearing MiYOSMART lenses with D.I.M.S. technology for eight years. That’s a significant stretch—and the findings held up.
The results showed sustained reductions in myopia progression and axial length growth over the full period. Specifically, the study found a mean myopia progression of -1.00D (± 0.41D, p=0.017) and axial elongation of 0.42 mm (± 0.18 mm, p=0.019) in children who continued lens wear throughout the study period.¹
“This landmark study… reveals that long-term MiYOSMART use continues to significantly slow myopia progression,” said Dr. Natalia Vlasak, global head of Medical and Scientific Affairs at HOYA Vision Care. “These findings emphasize the life-changing value of long-term adherence, providing crucial information and guidance for eye care professionals and parents committed to protecting children’s vision health for the future.”
READ MORE: Game-Changers in Myopia Management
What happens when you add atropine?
Next up was the ASPECT randomized controlled trial, and this one focused on combination therapy—MiYOSMART lenses plus 0.025% atropine drops.
According to the first 12-month results, this combination resulted in significantly lower axial elongation compared to atropine alone (0.07 mm vs. 0.18 mm; p<0.001).² Approximately 40% of children in the combination group showed no measurable progression. In addition, early analysis suggested potential benefits to vision-related quality of life, including general vision and competence.⁴
“Our findings suggest that combining MiYOSMART spectacle lenses with atropine can unlock even greater outcomes for children with myopia progression – marking a positive step towards more personalized, powerful treatment strategies in myopia management that suit the unique needs of each child,” Dr. Vlasak noted.
READ MORE: MOSAIC Study Unveils 3-Year Results on Atropine Regimens for Myopia Control
Can DIMS stop myopia before it starts?
Finally, HOYA introduced a first-of-its-kind pilot study looking at whether DIMS spectacle lenses could be useful for preventing the onset of myopia—specifically in children aged 5 to 6.
Over nine months, the average cycloplegic spherical equivalent refraction (SER) in kids wearing D.I.M.S. lenses remained stable with a yearly change of +0.06D, compared to -0.15D in the control group.³ While axial length increased slightly (from 22.48 mm to 22.64 mm; p<0.01), choroidal thickness remained stable throughout the period.
These results suggest D.I.M.S. lenses could have a protective effect in pre-myopic children—an area not widely explored before.
“With these studies, we continue to provide eye care professionals and parents with confidence through evidence for the benefits of MiYOSMART spectacle lenses, both as a monotherapy and in combination treatment,” Dr. Vlasak concluded.
Editor’s Note: The annual meeting of The Association for Research in Vision and Ophthalmology (ARVO 2025) was held from 4-8 May in Salt Lake City, Utah, United States.
Disclaimer: MiYOSMART spectacle lenses have not been approved for use in the management of myopia in all countries, including the U.S., and are not currently available for sale in all countries, including the U.S.
References
- Leung TW, et al. Comparison of Myopia Progression in Individuals Wearing Defocus Incorporated Multiple Segments (DIMS) Spectacle Lenses for Eight Years versus Shorter Durations. Poster number A0113. Presented 6th May, ARVO 2025.
- Guemes-Villahoz N, et al. Atropine and Spectacle lens Combination Treatment (ASPECT): 12-month results of a randomised controlled trial for myopia control using a combination of Defocus Incorporated Multiple Segments (DIMS) lenses and 0.025% atropine. Poster number B0466 . Presented 7th May, ARVO 2025.
- Yang HY, Tsai DC. Efficacy of Defocus Incorporated Multiple Segments (DIMS) Lenses in Retarding Myopic Shifts Among Pre-Myopic Preschoolers: Nine-Month Results of a Pilot Study. Poster number A0104. Presented 7th May, ARVO 2025.
- Garcia EH, et al. Vision-related quality of life in myopic children using combination treatment with atropine and DIMS (Defocus Incorporated Multiple Segments) spectacle lenses: 12-month results. Poster number A0297. Presented 5th May, ARVO 2025.
